WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Carol Walker Biography and Net Worth

SVP of Lantheus

Carol Walker has served as Senior Vice President, Quality since April 2018. She has overseen our Environment, Health and Safety department since December 2017. She joined Lantheus in February 2015 as Vice President, Quality. Carol brings more than 30 years of industry experience in quality and medical technology primarily in the medical device area. Prior to joining Lantheus, she served as Vice President of Quality Assurance and Regulatory Affairs for Intelligent Medical Devices, Inc. (IMDx), a company that designs, develops and manufactures in vitro diagnostic devices. Prior to that, Carol spent 11 years with Siemens Healthcare Diagnostics where she held positions of increasing responsibility, including Vice President of Quality Assurance. Earlier in her career, Carol held a variety of quality control positions during her 15 year tenure with Nova Biomedical, one of the 25 largest in vitro diagnostic companies in the world. Carol received a Bachelor of Science in Medical Technology from the Rochester Institute of Technology.

How do I contact Carol Walker?: The corporate mailing address for Mr. Walker and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected]. Learn More on Carol Walker's contact information.
Has Carol Walker been buying or selling shares of Lantheus?: Carol Walker has not been actively trading shares of Lantheus during the past quarter. Most recently, Carol Walker sold 15,000 shares of the business's stock in a transaction on Wednesday, March 30th. The shares were sold at an average price of $56.22, for a transaction totalling $843,300.00. Learn More on Carol Walker's trading history.
Who are Lantheus' active insiders?: Lantheus' insider roster includes Minnie Baylor-Henry (Director), Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (CEO & Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Gary Pruden (Director), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.
Are insiders buying or selling shares of Lantheus?: During the last year, Lantheus insiders bought shares 1 times. They purchased a total of 60,431,039 shares worth more than $57,409,487.05. During the last year, insiders at the medical equipment provider sold shares 13 times. They sold a total of 167,666 shares worth more than $12,647,453.05. The most recent insider tranaction occured on August, 12th when Director Gerard Ber sold 15,500 shares worth more than $1,495,440.00. Insiders at Lantheus own 1.5% of the company. Learn More about insider trades at Lantheus.
Information on this page was last updated on 8/12/2024.

Carol Walker Insider Trading History at Lantheus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/30/2022	Sell	15,000	$56.22	$843,300.00
3/4/2022	Sell	1,536	$49.98	$76,769.28
3/1/2022	Sell	6,956	$48.04	$334,166.24

Carol Walker Buying and Selling Activity at Lantheus

Lantheus Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Today's Range

Now: $89.29

$88.56

$91.69

50 Day Range

MA: $96.17

$76.22

$116.69

2 Week Range

Now: $89.29

$50.20

$126.89

Volume

2,181,956 shs

Average Volume

1,019,316 shs

Market Capitalization

$6.21 billion

P/E Ratio

14.86

Dividend Yield

N/A

Beta

0.45